|Mr. Richard H. Aldrich M.B.A., Mba||Co-Founder & Chairman||80k||N/A||1954|
|Dr. Roger D. Tung||Co-Founder, CEO, Pres & Exec. Director||914.16k||N/A||1960|
|Ms. Nancy Stuart||Chief Operating Officer||N/A||N/A||1958|
|Dr. James V. Cassella||Chief Devel. Officer||691.36k||N/A||1955|
|Mr. Marc A. Becker||CFO & Principal Accounting Officer||N/A||N/A||1972|
|Ms. Justine E. Koenigsberg||Sr. VP of Corp. Communications and Investor Relations||N/A||N/A||N/A|
|Mr. Jeffrey A. Munsie||Chief Legal Officer & Corp. Sec.||N/A||N/A||1977|
|Dr. Nabil Uddin Pharm.D.||VP of Corp. Devel.||N/A||N/A||N/A|
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Concert Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.